176 related articles for article (PubMed ID: 38725027)
1. Kinetics of glucose-6-phosphate dehydrogenase (G6PD) activity during Plasmodium vivax infection: implications for early radical malaria treatment.
Dahuron L; Goungounga J; Drame M; Douine M; Nacher M; Blaise T; Mosnier E; Musset L; Fouillet M; Djossou F; Epelboin L
Malar J; 2024 May; 23(1):140. PubMed ID: 38725027
[TBL] [Abstract][Full Text] [Related]
2. Primaquine alternative dosing schedules for preventing malaria relapse in people with Plasmodium vivax.
Milligan R; Daher A; Villanueva G; Bergman H; Graves PM
Cochrane Database Syst Rev; 2020 Aug; 8():CD012656. PubMed ID: 32816320
[TBL] [Abstract][Full Text] [Related]
3. UK malaria treatment guidelines 2016.
Lalloo DG; Shingadia D; Bell DJ; Beeching NJ; Whitty CJM; Chiodini PL;
J Infect; 2016 Jun; 72(6):635-649. PubMed ID: 26880088
[TBL] [Abstract][Full Text] [Related]
4. Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria.
Milligan R; Daher A; Graves PM
Cochrane Database Syst Rev; 2019 Jul; 7(7):CD012656. PubMed ID: 31274189
[TBL] [Abstract][Full Text] [Related]
5. Operational effectiveness of tafenoquine and primaquine for the prevention of Plasmodium vivax recurrence in Brazil: a retrospective observational study.
Brito M; Rufatto R; Brito-Sousa JD; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Batista Pereira D; Lacerda M
Lancet Infect Dis; 2024 Jun; 24(6):629-638. PubMed ID: 38452779
[TBL] [Abstract][Full Text] [Related]
6. Radical cure for Plasmodium vivax malaria after G6PD qualitative testing in four provinces in Cambodia, results from Phase I implementation.
Lek D; Tsai YC; Hirano J; Sovannaroth S; Bunreth V; Vonn P; Vannthen O; Bunkea T; Samphornarann T; Sokomar N; Sarath M; Kheang ST; Wong E; Burbach MK; Hughes J; Rekol H
Malar J; 2024 Feb; 23(1):56. PubMed ID: 38395925
[TBL] [Abstract][Full Text] [Related]
7. The risk of adverse clinical outcomes following treatment of Plasmodium vivax malaria with and without primaquine in Papua, Indonesia.
Thriemer K; Poespoprodjo JR; Kenangalem E; Douglas NM; Sugiarto P; Anstey NM; Simpson JA; Price RN
PLoS Negl Trop Dis; 2020 Nov; 14(11):e0008838. PubMed ID: 33175835
[TBL] [Abstract][Full Text] [Related]
8. G6PD testing and radical cure for Plasmodium vivax in Cambodia: A mixed methods implementation study.
Kheang ST; Ridley R; Ngeth E; Ir P; Ngor P; Sovannaroth S; Lek D; Phon S; Kak N; Yeung S
PLoS One; 2022; 17(10):e0275822. PubMed ID: 36264996
[TBL] [Abstract][Full Text] [Related]
9. [Role of primaquine in malaria control and elimination in French-speaking Africa].
Briolant S; Pradines B; Basco LK
Bull Soc Pathol Exot; 2017 Aug; 110(3):198-206. PubMed ID: 28417346
[TBL] [Abstract][Full Text] [Related]
10. Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria.
Llanos-Cuentas A; Lacerda MVG; Hien TT; Vélez ID; Namaik-Larp C; Chu CS; Villegas MF; Val F; Monteiro WM; Brito MAM; Costa MRF; Chuquiyauri R; Casapía M; Nguyen CH; Aruachan S; Papwijitsil R; Nosten FH; Bancone G; Angus B; Duparc S; Craig G; Rousell VM; Jones SW; Hardaker E; Clover DD; Kendall L; Mohamed K; Koh GCKW; Wilches VM; Breton JJ; Green JA
N Engl J Med; 2019 Jan; 380(3):229-241. PubMed ID: 30650326
[TBL] [Abstract][Full Text] [Related]
11. The haematological consequences of Plasmodium vivax malaria after chloroquine treatment with and without primaquine: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis.
Commons RJ; Simpson JA; Thriemer K; Chu CS; Douglas NM; Abreha T; Alemu SG; Añez A; Anstey NM; Aseffa A; Assefa A; Awab GR; Baird JK; Barber BE; Borghini-Fuhrer I; D'Alessandro U; Dahal P; Daher A; de Vries PJ; Erhart A; Gomes MSM; Grigg MJ; Hwang J; Kager PA; Ketema T; Khan WA; Lacerda MVG; Leslie T; Ley B; Lidia K; Monteiro WM; Pereira DB; Phan GT; Phyo AP; Rowland M; Saravu K; Sibley CH; Siqueira AM; Stepniewska K; Taylor WRJ; Thwaites G; Tran BQ; Hien TT; Vieira JLF; Wangchuk S; Watson J; William T; Woodrow CJ; Nosten F; Guerin PJ; White NJ; Price RN
BMC Med; 2019 Aug; 17(1):151. PubMed ID: 31366382
[TBL] [Abstract][Full Text] [Related]
12. Chloroquine-Primaquine versus Chloroquine Alone to Treat Vivax Malaria in Afghanistan: An Open Randomized Superiority Trial.
Awab GR; Imwong M; Bancone G; Jeeyapant A; Day NPJ; White NJ; Woodrow CJ
Am J Trop Med Hyg; 2017 Dec; 97(6):1782-1787. PubMed ID: 29141719
[TBL] [Abstract][Full Text] [Related]
13. Haemolysis in G6PD Heterozygous Females Treated with Primaquine for Plasmodium vivax Malaria: A Nested Cohort in a Trial of Radical Curative Regimens.
Chu CS; Bancone G; Moore KA; Win HH; Thitipanawan N; Po C; Chowwiwat N; Raksapraidee R; Wilairisak P; Phyo AP; Keereecharoen L; Proux S; Charunwatthana P; Nosten F; White NJ
PLoS Med; 2017 Feb; 14(2):e1002224. PubMed ID: 28170391
[TBL] [Abstract][Full Text] [Related]
14. Risk of hemolysis in Plasmodium vivax malaria patients receiving standard primaquine treatment in a population with high prevalence of G6PD deficiency.
Liu H; Zeng W; Malla P; Wang C; Lakshmi S; Kim K; Menezes L; Yang Z; Cui L
Infection; 2023 Feb; 51(1):213-222. PubMed ID: 35976559
[TBL] [Abstract][Full Text] [Related]
15. Operational feasibility of Plasmodium vivax radical cure with tafenoquine or primaquine following point-of-care, quantitative glucose-6-phosphate dehydrogenase testing in the Brazilian Amazon: a real-life retrospective analysis.
Brito M; Rufatto R; Murta F; Sampaio V; Balieiro P; Baía-Silva D; Castro V; Alves B; Alencar A; Duparc S; Grewal Daumerie P; Borghini-Fuhrer I; Jambert E; Peterka C; Edilson Lima F; Carvalho Maia L; Lucena Cruz C; Maciele B; Vasconcelos M; Machado M; Augusto Figueira E; Alcirley Balieiro A; Menezes A; Ataídes R; Batista Pereira D; Lacerda M
Lancet Glob Health; 2024 Mar; 12(3):e467-e477. PubMed ID: 38365417
[TBL] [Abstract][Full Text] [Related]
16. Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
Watson J; Taylor WRJ; Bancone G; Chu CS; Jittamala P; White NJ
PLoS Negl Trop Dis; 2018 Apr; 12(4):e0006440. PubMed ID: 29677199
[TBL] [Abstract][Full Text] [Related]
17. Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.
Rajapakse S; Rodrigo C; Fernando SD
Cochrane Database Syst Rev; 2015 Apr; 2015(4):CD010458. PubMed ID: 25921416
[TBL] [Abstract][Full Text] [Related]
18. Multiple relapses of Plasmodium vivax malaria acquired from West Africa and association with poor metabolizer CYP2D6 variant: a case report.
He X; Pan M; Zeng W; Zou C; Pi L; Qin Y; Zhao L; Qin P; Lu Y; Baird JK; Huang Y; Cui L; Yang Z
BMC Infect Dis; 2019 Aug; 19(1):704. PubMed ID: 31399061
[TBL] [Abstract][Full Text] [Related]
19. Management of relapsing Plasmodium vivax malaria.
Chu CS; White NJ
Expert Rev Anti Infect Ther; 2016 Oct; 14(10):885-900. PubMed ID: 27530139
[TBL] [Abstract][Full Text] [Related]
20. Prevalence of G6PD deficiency and submicroscopic malaria parasites carriage in malaria hotspot area in Northwest, Tanzania.
Manjurano A; Lyimo E; Kishamawe C; Omolo J; Mosha J; Donald M; Kazyoba P; Kapiga S; Changalucha J
Malar J; 2023 Dec; 22(1):372. PubMed ID: 38062464
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
